将VacA用作疫苗抗原。
Use of VacA as a Vaccine Antigen.
作者信息
Moyat Mati, Velin Dominique
机构信息
Service of Gastroenterology and Hepatology, Department of Medicine, Lausanne University Hospital, CLE D203, CHUV, 155 Chemin des Boveresses, CH-1066 Epalinges, Switzerland.
出版信息
Toxins (Basel). 2016 Jun 8;8(6):181. doi: 10.3390/toxins8060181.
Abstract
One of the major toxins secreted by H. pylori is the Vacuolating cytotoxin A (VacA) named after its ability to induce the formation of "vacuole"-like membrane vesicles in the cytoplasm of gastric cells. VacA has been associated with the disruption of mitochondrial functions, stimulation of apoptosis, blockade of T cell proliferation and promotion of regulatory T cells, thereby making it a promising vaccine target. Immunity to bacterial virulence factors is well known to protect humans against bacterial infections; hence, detoxified VacA has been evaluated as a vaccine antigen. Our short review summarizes the pre-clinical and clinical data that have been published on the use of VacA in the development of the H. pylori vaccine.
摘要
幽门螺杆菌分泌的主要毒素之一是空泡毒素A（VacA），它因能够在胃细胞胞质中诱导形成“空泡”样膜泡而得名。VacA与线粒体功能破坏、细胞凋亡刺激、T细胞增殖阻断以及调节性T细胞的促进有关，因此使其成为一个有前景的疫苗靶点。众所周知，对细菌毒力因子的免疫可保护人类免受细菌感染；因此，已对解毒的VacA作为疫苗抗原进行了评估。我们的简短综述总结了已发表的关于在幽门螺杆菌疫苗研发中使用VacA的临床前和临床数据。
相似文献
1
Use of VacA as a Vaccine Antigen.将VacA用作疫苗抗原。
Toxins (Basel). 2016 Jun 8;8(6):181. doi: 10.3390/toxins8060181.
2
Vacuolating cytotoxin A (VacA) - A multi-talented pore-forming toxin from Helicobacter pylori.空泡毒素A（VacA）——一种来自幽门螺杆菌的多功能成孔毒素。
Toxicon. 2016 Aug;118:27-35. doi: 10.1016/j.toxicon.2016.04.037. Epub 2016 Apr 20.
3
Antigenic diversity among Helicobacter pylori vacuolating toxins.幽门螺杆菌空泡毒素之间的抗原多样性。
Infect Immun. 2001 Jul;69(7):4329-36. doi: 10.1128/IAI.69.7.4329-4336.2001.
4
Novel activities of the Helicobacter pylori vacuolating cytotoxin: from epithelial cells towards the immune system.幽门螺杆菌空泡毒素的新活性：从上皮细胞到免疫系统
Int J Med Microbiol. 2004 Apr;293(7-8):539-47. doi: 10.1078/1438-4221-00300.
5
Release of Helicobacter pylori vacuolating cytotoxin by both a specific secretion pathway and budding of outer membrane vesicles. Uptake of released toxin and vesicles by gastric epithelium.幽门螺杆菌空泡毒素通过特定分泌途径和外膜囊泡出芽释放。胃上皮细胞摄取释放的毒素和囊泡。
J Pathol. 1999 Jun;188(2):220-6. doi: 10.1002/(SICI)1096-9896(199906)188:2<220::AID-PATH307>3.0.CO;2-C.
6
Vacuolating cytotoxin of Helicobacter pylori induces apoptosis in the human gastric epithelial cell line AGS.幽门螺杆菌空泡毒素诱导人胃上皮细胞系AGS发生凋亡。
Infect Immun. 2001 Aug;69(8):5080-7. doi: 10.1128/IAI.69.8.5080-5087.2001.
7
The design of vaccines against Helicobacter pylori and their development.抗幽门螺杆菌疫苗的设计及其研发。
Annu Rev Immunol. 2001;19:523-63. doi: 10.1146/annurev.immunol.19.1.523.
8
Helicobacter pylori vacA genotypes and cagA gene in a series of 383 H. pylori-positive patients.383例幽门螺杆菌阳性患者中幽门螺杆菌vacA基因型和cagA基因情况
Z Gastroenterol. 2000 Jul;38(7):559-64. doi: 10.1055/s-2000-7449.
9
Helicobacter pylori vacuolating cytotoxin induces apoptosis via activation of endoplasmic reticulum stress in dendritic cells.幽门螺杆菌空泡毒素通过激活树突状细胞内质网应激诱导细胞凋亡。
J Gastroenterol Hepatol. 2015 Jan;30(1):99-108. doi: 10.1111/jgh.12663.
10
An Overview of Helicobacter pylori VacA Toxin Biology.幽门螺杆菌空泡毒素生物学概述
Toxins (Basel). 2016 Jun 3;8(6):173. doi: 10.3390/toxins8060173.
引用本文的文献
1
Treatment with (R)-α-methylhistamine or IL4 stimulates mucin production and decreases density in the murine stomach.用（R）-α-甲基组胺或白细胞介素4进行治疗可刺激小鼠胃中粘蛋白的产生并降低其密度。
Virulence. 2025 Dec;16(1):2530173. doi: 10.1080/21505594.2025.2530173. Epub 2025 Jul 16.
2
Construction and evaluation of a minicell-based dendritic cell-targeted multi-epitope vaccine against .一种基于微小细胞的靶向树突状细胞的多表位疫苗的构建与评价，用于对抗…… （原文此处不完整）
Front Immunol. 2025 Jun 5;16:1595096. doi: 10.3389/fimmu.2025.1595096. eCollection 2025.
3
Pivotal role of virulence genes in pathogenicity and vaccine development.毒力基因在致病性和疫苗开发中的关键作用。
Front Med (Lausanne). 2025 Jan 6;11:1523991. doi: 10.3389/fmed.2024.1523991. eCollection 2024.
4
Design of a multi-epitope vaccine based on immunoinformatics.基于免疫信息学的多表位疫苗设计。
Front Immunol. 2024 Aug 23;15:1432968. doi: 10.3389/fimmu.2024.1432968. eCollection 2024.
5
Outer Membrane Vesicles (OMVs) as Biomedical Tools and Their Relevance as Immune-Modulating Agents against Infections: Current Status and Future Prospects.外膜囊泡（OMVs）作为生物医学工具及其作为抗感染免疫调节剂的相关性：现状和未来展望。
Int J Mol Sci. 2023 May 10;24(10):8542. doi: 10.3390/ijms24108542.
6
Protective immunity enhanced vaccine vectors delivering antigens reduce stomach colonization in mice.携带抗原的增强保护性免疫疫苗载体可减少小鼠胃定植。
Front Immunol. 2022 Nov 18;13:1034683. doi: 10.3389/fimmu.2022.1034683. eCollection 2022.
7
Oral Immunization With a M Cell-Targeting Recombinant Vaccine LL-plSAM-FVpE Stimulate Protective Immunity Against in Mice.口服黏膜免疫用 M 细胞靶向重组疫苗 LL-plSAM-FVpE 刺激小鼠产生针对 的保护性免疫。
Front Immunol. 2022 Jul 7;13:918160. doi: 10.3389/fimmu.2022.918160. eCollection 2022.
8
Antigenic and conserved peptides from diverse Helicobacter pylori antigens.来自不同幽门螺杆菌抗原的抗原性和保守肽。
Biotechnol Lett. 2022 Mar;44(3):535-545. doi: 10.1007/s10529-022-03238-x. Epub 2022 Mar 11.
9
Metabolic reprogramming results in abnormal glycolysis in gastric cancer: a review.代谢重编程导致胃癌中糖酵解异常：综述
Onco Targets Ther. 2019 Feb 13;12:1195-1204. doi: 10.2147/OTT.S189687. eCollection 2019.
10
Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy.VacA毒素在宿主细胞中的多效性细胞毒性及其对免疫治疗的影响。
Bioimpacts. 2017;7(1):59-71. doi: 10.15171/bi.2017.08. Epub 2017 Mar 30.
本文引用的文献
1
IL-22-induced antimicrobial peptides are key determinants of mucosal vaccine-induced protection against H. pylori in mice.白细胞介素-22诱导的抗菌肽是黏膜疫苗诱导小鼠抵抗幽门螺杆菌感染的关键决定因素。
Mucosal Immunol. 2017 Jan;10(1):271-281. doi: 10.1038/mi.2016.38. Epub 2016 May 4.
2
Role of bismuth in improving Helicobacter pylori eradication with triple therapy.铋在三联疗法提高幽门螺杆菌根除率中的作用。
Gut. 2016 May;65(5):870-8. doi: 10.1136/gutjnl-2015-311019. Epub 2016 Feb 4.
3
Role of Inflammatory Monocytes in Vaccine-Induced Reduction of Helicobacter felis Infection.炎症单核细胞在疫苗诱导减少幽门螺杆菌感染中的作用。
Infect Immun. 2015 Nov;83(11):4217-28. doi: 10.1128/IAI.01026-15. Epub 2015 Aug 17.
4
Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial.中国儿童口服重组幽门螺杆菌疫苗的有效性、安全性和免疫原性：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2015 Oct 10;386(10002):1457-64. doi: 10.1016/S0140-6736(15)60310-5. Epub 2015 Jun 30.
5
At last, vaccine-induced protection against Helicobacter pylori.最后，疫苗诱导的针对幽门螺杆菌的保护作用。
Lancet. 2015 Oct 10;386(10002):1424-5. doi: 10.1016/S0140-6736(15)60579-7. Epub 2015 Jun 30.
6
Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits.幽门螺杆菌最新进展：胃癌、可靠的治疗方法及潜在益处
Gastroenterology. 2015 Apr;148(4):719-31.e3. doi: 10.1053/j.gastro.2015.01.040. Epub 2015 Feb 2.
7
Immune responses to Helicobacter pylori infection.对幽门螺杆菌感染的免疫反应。
World J Gastroenterol. 2014 May 21;20(19):5583-93. doi: 10.3748/wjg.v20.i19.5583.
8
A role for the vacuolating cytotoxin, VacA, in colonization and Helicobacter pylori-induced metaplasia in the stomach.空泡细胞毒素 VacA 在定植和幽门螺杆菌诱导胃黏膜化生中的作用。
J Infect Dis. 2014 Sep 15;210(6):954-63. doi: 10.1093/infdis/jiu154. Epub 2014 Mar 12.
9
Diet, microbial virulence, and Helicobacter pylori-induced gastric cancer.饮食、微生物毒力和幽门螺杆菌引起的胃癌。
Gut Microbes. 2013 Nov-Dec;4(6):482-93. doi: 10.4161/gmic.26262. Epub 2013 Sep 3.
10
Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance.幽门螺杆菌 γ-谷氨酰转肽酶和空泡细胞毒素促进胃的持续存在和免疫耐受。
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3047-52. doi: 10.1073/pnas.1211248110. Epub 2013 Feb 4.
Zotero 插件